ADMA241220C22000
- 0.30
- -0.05-14.29%
ADMA Biologics Newsroom
Can Adma Biologics (ADMA) Climb 25.5% to Reach the Level Wall Street Analysts Expect?
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating
10 Health Care Stocks With Whale Alerts In Today's Session
ADMA Biologics (NASDAQ:ADMA) Seems To Use Debt Quite Sensibly
Adma Biologics (ADMA) Is on the Move, Here's Why the Trend Could Be Sustainable
Insider Sale: CFO and Treasurer of $ADMA (ADMA) Sells 15,000 Shares
ADMA Biologics Announces Board Resignations and Appointments
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $24
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet
NASDAQ New 52-Week Highs And Lows
Earnings Beat: Here's What ADMA Biologics, Inc. (NASDAQ:ADMA) Analysts Are Forecasting For Next Year
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $24
ADMA Biologics Is Maintained at Strong Buy by Raymond James
ADMA Biologics Analyst Ratings
H.C. Wainwright Maintains ADMA Biologics(ADMA.US) With Buy Rating, Raises Target Price to $26
Adma Biologics Price Target Raised to $26 From $18 at H.C. Wainwright
ADMA Biologics, Inc. (ADMA) Q3 2024 Earnings Call Transcript Summary
ADMA Biologics, Inc. (ADMA) Q3 2024 Earnings Call Transcript
ADMA Biologics | 10-Q: Q3 2024 Earnings Report
Express News | ADMA Biologics FY 2024 and 2025 Total Revenue Guidance Increased to More Than $415 Million and $465 Million, Respectively